Chemours (NYSE: CC) reported Q1 EPS of $0.32, $0.17 better than the analyst estimate of $0.15. Revenue for the quarter came in at $1.35 billion versus the consensus estimate of $1.35 billion.

Outlook

In the second quarter of 2024, the Company expects TT to achieve sequential Net Sales growth of approximately 15%, reflecting the previously communicated improvement in the Company’s TiO2 orderbook. Adjusted EBITDA growth is expected to be generally in-line with the growth in Net Sales, with higher volumes and improved fixed cost absorption, partially offset primarily by the shift in timing of higher-cost ore consumption, much of which is anticipated for the second quarter.

For earnings history and earnings-related data on Chemours (CC) click here.